Z Younossi

Summary

Affiliation: Inova Fairfax Hospital
Country: USA

Publications

  1. ncbi request reprint Monoclonal and polyclonal antibodies against the HCV envelope proteins
    Heshaam M Mir
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Clin Liver Dis 13:477-86. 2009
  2. ncbi request reprint Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States Electronic address
    J Hepatol 61:228-34. 2014
  3. pmc Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
    Aybike Birerdinc
    Center for Liver Disease, Inova Health System Falls Church, Virginia School of Systems Biology, College of Science, George Mason University Fairfax, Virginia
    Brain Behav 2:525-31. 2012
  4. pmc Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD
    Rohini Mehta
    Betty and Guy Beatty Obesity and Liver Program, Inova Health System, Falls Church, VA 22042, USA
    Mediators Inflamm 2013:684237. 2013
  5. doi request reprint Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA Electronic address
    J Hepatol 60:741-7. 2014
  6. doi request reprint Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA Electronic address
    J Hepatol 60:530-7. 2014
  7. doi request reprint Nonalcoholic fatty liver disease in lean individuals in the United States
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Medicine (Baltimore) 91:319-27. 2012
  8. doi request reprint Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
    Z M Younossi
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    J Viral Hepat 20:550-5. 2013
  9. pmc Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS)
    Ancha Baranova
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA
    J Transl Med 11:133. 2013
  10. doi request reprint Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Z M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 37:703-9. 2013

Collaborators

Detail Information

Publications75

  1. ncbi request reprint Monoclonal and polyclonal antibodies against the HCV envelope proteins
    Heshaam M Mir
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Clin Liver Dis 13:477-86. 2009
    ..Monoclonal and polyclonal antibodies present an important therapeutic option in this area, and this article assesses current investigations of several antibodies...
  2. ncbi request reprint Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States Electronic address
    J Hepatol 61:228-34. 2014
    ..Interferon (IFN) negatively impacts patients' well-being and patient-reported outcomes (PROs). Our aim was to assess PROs during treatment with an IFN-free regimen [sofosbuvir (SOF)+ribavirin (RBV)]...
  3. pmc Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
    Aybike Birerdinc
    Center for Liver Disease, Inova Health System Falls Church, Virginia School of Systems Biology, College of Science, George Mason University Fairfax, Virginia
    Brain Behav 2:525-31. 2012
    ..With further validation, TGF-β1 and other components of Th1/Th2 regulation pathway may provide a future marker for CH-C patients predisposed to depression...
  4. pmc Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD
    Rohini Mehta
    Betty and Guy Beatty Obesity and Liver Program, Inova Health System, Falls Church, VA 22042, USA
    Mediators Inflamm 2013:684237. 2013
    ..The results of our study suggest that changes in expression patterns for inflammatory molecule encoding genes within gastric tissue may contribute to the pathogenesis of obesity-related NAFLD...
  5. doi request reprint Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA Electronic address
    J Hepatol 60:741-7. 2014
    ..Currently, there is no published data assessing the impact of interferon-free regimens on HRQL. The aim is to report the HRQL of patients who participated in clinical trials of sofosbuvir (SOF) for CH-C...
  6. doi request reprint Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA Electronic address
    J Hepatol 60:530-7. 2014
    ..The aim is to determine cost-effectiveness of staging-guided vs. treat all HCV genotype-1 patients with interferon-based vs. interferon-free regimens...
  7. doi request reprint Nonalcoholic fatty liver disease in lean individuals in the United States
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Medicine (Baltimore) 91:319-27. 2012
    ..05). Therefore, we conclude that lean individuals with NAFLD have a different clinical profile than overweight-obese individuals with NAFLD. Furthermore, patients with NASH are commonly Hispanic and have components of metabolic syndrome...
  8. doi request reprint Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
    Z M Younossi
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    J Viral Hepat 20:550-5. 2013
    ..Therefore, birth cohort screening of the U.S. General population could lead to wider identification of HCV and potentially better management of the future burden of HCV and its complications...
  9. pmc Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS)
    Ancha Baranova
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA
    J Transl Med 11:133. 2013
    ....
  10. doi request reprint Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Z M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 37:703-9. 2013
    ..The impact of moderate alcohol consumption on long-term outcomes of chronic hepatitis C (CH-C) infected patients remains controversial...
  11. doi request reprint Associations of chronic hepatitis C with metabolic and cardiac outcomes
    Z M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 37:647-52. 2013
    ..Chronic hepatitis C virus (CH-C) infection is associated with metabolic conditions such as insulin resistance and type 2 diabetes (DM) and may increase the risk of cardiovascular diseases...
  12. ncbi request reprint In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not
    Zobair M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA
    Metabolism 62:352-60. 2013
    ..The aim of this study is to compare the clinical profile and long-term outcome in NAFLD patients with or without metabolic syndrome...
  13. pmc The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
    Zobair M Younossi
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    J Transl Med 10:25. 2012
    ..We aimed to assess whether IL28B alleles rs12979860 genotype influences gene expression in response to PEG-IFN/RBV in CH-C patients...
  14. pmc Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples
    Rohini Mehta
    Molecular and Microbiology Department and Center for the Study of Genomics in Liver Diseases, George Mason University, Fairfax, VA, USA
    BMC Mol Biol 11:39. 2010
    ..In this study we validated candidate reference genes suitable for qRT-PCR profiling experiments using visceral adipose samples from obese and lean individuals...
  15. pmc Non-invasive markers for hepatic fibrosis
    Ancha Baranova
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    BMC Gastroenterol 11:91. 2011
    ..This review provides a systematic overview of these techniques, as well as both direct and indirect biomarkers based approaches used to stage fibrosis and covers recent developments in this rapidly advancing area...
  16. doi request reprint Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response
    Zobair M Younossi
    Inova Fairfax Hospital, Falls Church, VA, USA
    Liver Int 29:3-12. 2009
    ..Clinically, these data suggest that attention must be paid not only to optimizing antiviral response but also to screening for and treatment of the various components of the metabolic syndrome...
  17. doi request reprint A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 18:1430-7. 2008
    ..Recent findings suggest a role for apoptosis and adipocytokines in the pathogenesis of NASH. The aim of this study was to develop a noninvasive diagnostic biomarker for NASH...
  18. doi request reprint Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Clin Gastroenterol Hepatol 8:718-23. 2010
    ..We performed a population-based study to assess factors that are associated independently with hepatocellular carcinoma (HCC)-related mortality...
  19. doi request reprint Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Proteome Res 9:3218-24. 2010
    ..Phosphoproteomics technology could potentially be used to provide pathogenic information about NASH and NASH-related fibrosis. This information can lead to a clinically relevant diagnostic/prognostic biomarker for NASH...
  20. doi request reprint Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Liver Int 29:1403-12. 2009
    ..Hepatic steatosis occurs in 40-70% of patients chronically infected with hepatitis C virus [chronic hepatitis C (CH-C)]. Hepatic steatosis in CH-C is associated with progressive liver disease and a low response rate to antiviral therapy...
  21. ncbi request reprint Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 49:763-74. 2009
    ..Conclusion: Early gene expression during anti-HCV therapy may elucidate important molecular pathways that may be influencing the probability of achieving virologic response...
  22. doi request reprint A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Obes Surg 21:431-9. 2011
    ..Patients with biopsy-proven NASH and especially those with fibrosis are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH-related fibrosis...
  23. doi request reprint Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV)
    Zobair M Younossi
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Falls Church, Virginia, 22042, USA
    J Proteome Res 10:774-9. 2011
    ..Signaling events elucidated in the study may shed some light into molecular mechanisms of response to anti-HCV treatment...
  24. ncbi request reprint A 2012 clinical update for internists in adult nonalcoholic fatty liver disease
    Z M Younossi
    Department of Internal Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Panminerva Med 54:29-37. 2012
    ..In this article, we aim to provide an update to clinicians related to issues surrounding prognosis, monitoring, and treatment...
  25. doi request reprint Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population
    Zobair M Younossi
    Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA
    Hepatology 54:1167-78. 2011
    ..On the other hand, QM for HepB increased from 31.7% ± 0.9% to 40.7% ± 1.0% in the population, whereas no changes in QM were noted in any diagnostic cohort except for NAFLD...
  26. doi request reprint Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA
    Clin Gastroenterol Hepatol 9:524-530.e1; quiz e60. 2011
    ..Chronic liver diseases (CLDs) are major causes of morbidity and mortality worldwide. We assessed changes in the prevalence of different types of CLD in the United States...
  27. doi request reprint Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Z M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 28:2-12. 2008
    ..Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome...
  28. ncbi request reprint Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C
    Zobair M Younossi
    Inova Fairfax Hospital, Center for Liver Diseases, Department of Medicine, Falls Church, Virginia 22042, USA
    Dig Dis Sci 50:970-5. 2005
    ..29 vs. 20%; P = 0.04). Age, gender, and BMI did not affect SVR. The addition of amantadine to pegylated interferon alpha-2b and ribavirin does not seem to increase the efficicacy of this regimen...
  29. ncbi request reprint The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin
    Rochelle S Collantes
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    J Clin Gastroenterol 39:S9-13. 2005
    ....
  30. ncbi request reprint Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Cleve Clin J Med 71:S17-21. 2004
    ..The impact of growth factors on sustained virologic response and their cost-effectiveness in patients with chronic hepatitis C need further assessment...
  31. ncbi request reprint Clinical predictors of fibrosis in patients with chronic liver disease
    M Stepanova
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 31:1085-94. 2010
    ..Patients with chronic liver disease and components of metabolic syndrome may be at higher risk for fibrosis...
  32. ncbi request reprint Non-invasive diagnostic tests for non-alcoholic fatty liver disease
    J M Estep
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Curr Mol Med 10:166-72. 2010
    ..01 percent being fatal. This review examines the current strategies for development of the non-invasive techniques that will one day replace liver biopsy and serve as a non-invasive gold standard for the diagnosis and staging of NASH...
  33. ncbi request reprint Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome
    Chin Hee Kim
    Center for Liver Diseases INOVA Fairfax Hospital, Falls Church, VA 22042, USA
    Cleve Clin J Med 75:721-8. 2008
    ..There is no established treatment for NAFLD except for weight loss and treating each component of the metabolic syndrome...
  34. ncbi request reprint Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life
    Amy A Dan
    Center for Liver Diseases, Dept of Psychiatry, Inova Fairfax Hospital, Annandale, VA 22003 6800, USA
    Psychosomatics 48:223-9. 2007
    ..Greater anger was associated with more depression and poorer HRQL. Findings point to the importance for physicians to screen for a wide range of neuropsychiatric side effects of interferon, including anger...
  35. ncbi request reprint Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA 22042, USA
    Obes Surg 17:1111-8. 2007
    ..Differences in transcriptional regulation in omental adipose tissue and liver tissue may provide important insights into the pathogenesis of NAFLD and its progression...
  36. ncbi request reprint Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Washington, DC, USA
    Obes Surg 15:310-5. 2005
    ..We report the prevalence of NAFLD and NASH as well as predictors of NASH and advanced fibrosis in morbidly obese patients...
  37. ncbi request reprint Current treatment strategies for non-alcoholic fatty liver disease (NAFLD)
    Poonam Mishra
    Center for Liver Diseases at Inova Fairfax Hospital, Annandale, Virginia 22042, USA
    Curr Drug Discov Technol 4:133-40. 2007
    ..NAFLD treatment currently focuses on reducing metabolic risk factors, with the mainstay of therapy focusing on life-style modifications such as gradual weight loss through diet and regular exercise...
  38. ncbi request reprint Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C
    Nila Rafiq
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Expert Rev Gastroenterol Hepatol 2:207-15. 2008
    ..g., HCV genotype 3). Increasing evidence suggests that hepatic steatosis, insulin resistance and obesity in the setting of HCV have a negative impact on the efficacy of treatment and hepatic progression of fibrosis...
  39. doi request reprint Nutritional assessments of patients with non-alcoholic fatty liver disease
    Chin Hee Kim
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Obes Surg 20:154-60. 2010
    ..Obesity is not only associated with nonalcoholic fatty liver disease (NAFLD) but it also adversely affects the progression of other liver diseases. There are limited data regarding the dietary habits of patients with chronic liver disease...
  40. doi request reprint Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
    Maria Stepanova
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Gut 59:1410-5. 2010
    ..Chronic liver disease (CLD) is a major cause of mortality and morbidity worldwide. The aim of this study was to assess the overall and liver-related mortality and their predictors in patients with CLD using population data...
  41. ncbi request reprint Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Liver Int 25:760-71. 2005
    ..NAFLD includes a spectrum of clinicopathologic syndromes that includes non-alcoholic steatohepatitis (NASH) that has potential for progression. The pathogenesis of NASH is poorly characterized...
  42. ncbi request reprint Depression, anemia and health-related quality of life in chronic hepatitis C
    Amy A Dan
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 3289 Woodburn Road, Suite 375, Annandale, VA 22003 6800, USA
    J Hepatol 44:491-8. 2006
    ..Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia...
  43. doi request reprint Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis
    J Michael Estep
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 19:617-24. 2009
    ..The aim of this study was to assess the association of hepatic fibrosis and NASH by evaluating the intrinsic differences in the inflammatory cytokine signaling in the visceral adipose tissue obtained from morbidly obese patients...
  44. ncbi request reprint Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Clin Gastroenterol 38:705-9. 2004
    ..Superimposed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) may affect HCV-related fibrosis. We performed a study to determine the relationship between NAFLD and chronic hepatitis C...
  45. ncbi request reprint Impact of non-alcoholic fatty liver disease on chronic hepatitis B
    Silvia Bondini
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22003 6800, USA
    Liver Int 27:607-11. 2007
    ..Aim: This study aims to evaluate the prevalence of NAFLD in patients with CH-B and the association with viral and host factors, particularly in patients with metabolic syndrome (MS)...
  46. ncbi request reprint Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery
    Savita Srivastava
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Hepatology 42:490-2. 2005
    ..This study examines the impact of biliopancreatic diversion, a malabsorptive variant of gastric bypass, on liver histology...
  47. ncbi request reprint Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, VA, USA
    Expert Rev Mol Diagn 7:195-205. 2007
    ..Potential therapeutic applications are also considered...
  48. ncbi request reprint Microarray technology in the study of obesity and non-alcoholic fatty liver disease
    Ancha Baranova
    Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University and Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Liver Int 25:1091-6. 2005
    ..Over the next few years, advances in technology and refinements in study design and data analysis will make clinically relevant translational research even more engaging and productive...
  49. ncbi request reprint High rates of uninsured among HCV-positive individuals
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003, USA
    J Clin Gastroenterol 39:826-30. 2005
    ..There are no published data on the health insurance status of Hepatitis C virus (HCV)-positive individuals. To address this issue, we analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III)...
  50. ncbi request reprint Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection
    Jillian Kallman
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, 3289 Woodburn Road, Suite 375, Annandale, Virginia 22003, USA
    Dig Dis Sci 52:2531-9. 2007
    ..Chronic HCV infection has a profound negative impact on patients' HRQL. Disabling fatigue is the most important factor that contributes to loss of well-being in this relatively young group of patients...
  51. ncbi request reprint A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis
    Valerie S Calvert
    George Mason Inova Health System s Translational Research Centers, VA, USA
    Hepatology 46:166-72. 2007
    ..Specific insulin pathway signaling events are altered in the adipose tissue of patients with NASH compared with patients with nonprogressive forms of NAFLD...
  52. ncbi request reprint Nonalcoholic fatty liver disease: an agenda for clinical research
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 35:746-52. 2002
  53. doi request reprint Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis
    Poonam Mishra
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22033, USA
    Liver Int 28:1080-6. 2008
    ..This study evaluates the potential association between the NAFLD subtypes and a number of polysomnographical (PSG) parameters...
  54. doi request reprint Effects of weight loss on nonalcoholic fatty liver disease
    Nila Rafiq
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Semin Liver Dis 28:427-33. 2008
    ..On the other hand, the literature lacks well-designed, randomized control trials that assess the efficacy of anti-obesity regimens on histologic and long-term outcomes of NAFLD...
  55. doi request reprint Nonalcoholic fatty liver disease: a practical approach to evaluation and management
    Nila Rafiq
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Clin Liver Dis 13:249-66. 2009
    ..Although there are no approved treatment regimens for NAFLD or NASH, a number of different interventions are being tested. Meanwhile, most experts advocate that components of metabolic syndrome should be effectively treated...
  56. ncbi request reprint Obesity-related differential gene expression in the visceral adipose tissue
    Ancha Baranova
    Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, VA, USA
    Obes Surg 15:758-65. 2005
    ..This study investigates the expression patterns in human adipose tissue, and identifies genes that may be involved in the abnormal energy homeostasis...
  57. ncbi request reprint Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Obes Surg 16:1118-25. 2006
    ....
  58. ncbi request reprint Risk factors for hepatocellular carcinoma in patients with cirrhosis
    Steedman A Sarbah
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Dig Dis Sci 49:850-3. 2004
    ..8 [1.9-134]; P = 0.01). Iron studies did not reveal an increased risk for iron overload or HFE mutation. Male gender, advancing age, and non-Caucasian ethnic background are independently associated with HCC...
  59. ncbi request reprint Approach to the diagnosis and treatment of nonalcoholic fatty liver disease
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Clin Liver Dis 9:617-34, vi. 2005
    ..This article describes the epidemiology, clinical features, natural history, and pathogenesis of NAFLD...
  60. ncbi request reprint Non-alcoholic fatty liver disease: an overview
    Brian P Mulhall
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Gastroenterol Hepatol 17:1136-43. 2002
    ..It is anticipated that, through a better understanding of NAFL, more effective treatment protocols can be developed targeting only those patients with NASH that are at the highest risk for progression to cirrhosis and liver failure...
  61. ncbi request reprint A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 42:665-74. 2005
    ..These findings may help clarify the pathogenesis of NAFLD and identify potential targets for therapeutic intervention...
  62. doi request reprint Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index
    Amy A Dan
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22003 6800, USA
    Liver Transpl 14:321-6. 2008
    ..In conclusion, SF-6D provides not only a generic assessment of HRQL but also a utility score that can be used for economic analysis of patients with chronic liver disease...
  63. doi request reprint Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003, USA
    J Hepatol 49:608-12. 2008
    ..The natural history of non-alcoholic fatty liver disease (NAFLD) remains to be defined. We conducted a study to determine the overall and liver-related mortality of NAFLD in the general US population...
  64. doi request reprint Metabolic syndrome after laparoscopic bariatric surgery
    Clare Nugent
    Center for Liver Diseases, Inova Fairfax Hospital and Translational Research Institute, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 18:1278-86. 2008
    ..Metabolic syndrome (MS) is common among morbidly obese patients undergoing bariatric surgery. The aim of this study was to assess the impact and predictors of bariatric surgery on the resolution of MS...
  65. doi request reprint Long-term follow-up of patients with nonalcoholic fatty liver
    Nila Rafiq
    Center for Liver Diseases, Inova Health System, Annandale, Virginia, USA
    Clin Gastroenterol Hepatol 7:234-8. 2009
    ..NASH is the only subtype of NAFLD that has been shown to progress relatively, although these findings were reported from studies with short follow-up periods. We assessed the long-term outcomes of a NAFLD cohort...
  66. ncbi request reprint Evaluation and management of obesity-related nonalcoholic fatty liver disease
    Clare Nugent
    Inova Fairfax Hospital Annandale, VA 22042, USA
    Nat Clin Pract Gastroenterol Hepatol 4:432-41. 2007
    ..As yet there is no convincingly effective treatment for NAFLD--a multimodal treatment plan that targets obesity, insulin resistance, hyperlipidemia and hypertension might be the best option for these patients...
  67. ncbi request reprint Health-related quality of life in patients with chronic hepatitis B
    Silvia Bondini
    Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA, USA
    Liver Int 27:1119-25. 2007
    ..Although chronic hepatitis C (CH-C) has consistently been shown to impair patients' health-related quality of life (HRQL), the impact of chronic hepatitis B (CH-B) on HRQL has not been fully explored...
  68. doi request reprint Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation
    J Michael Estep
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Dig Dis Sci 55:496-504. 2010
    ..Hepatic stellate cells (HSC) are involved in hepatic fibrogenesis. Cell signaling associated with an insult to the liver affects an HSC transdifferentiation to fibrogenic myofibroblast-like cells...
  69. ncbi request reprint Nonalcoholic fatty liver disease and the epidemic of obesity
    Rochelle Collantes
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042 3300, USA
    Cleve Clin J Med 71:657-64. 2004
    ..Nonalcoholic fatty liver disease (NAFLD) is common in patients with the metabolic syndrome, and it is expected to become more common in countries where obesity, one of the components of the metabolic syndrome, is increasing...
  70. doi request reprint Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Hepatology 53:1874-82. 2011
    ..Among the individual pathologic features, advanced fibrosis showed the best independent association with LRM [adjusted hazard ratio = 5.68 (95% confidence interval = 1.50-21.45)]...
  71. ncbi request reprint Treatment regimens for non-alcoholic fatty liver disease
    Brian P Lam
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Ann Hepatol 8:S51-9. 2009
    ....
  72. ncbi request reprint The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Department of Medicine, Falls Church, VA 22042, USA
    Clin Liver Dis 11:209-20, xi. 2007
    ..For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD...
  73. doi request reprint When and how to evaluate mildly elevated liver enzymes in apparently healthy patients
    George Aragon
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Cleve Clin J Med 77:195-204. 2010
    ....
  74. ncbi request reprint Pathologic assessment of non-alcoholic fatty liver disease
    Silvia Bondini
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Clin Liver Dis 11:17-23, vii. 2007
    ..This article reviews some of the studies dealing with the histopathology of NAFLD, with attempts to develop a standardized pathologic scoring system for NASH...
  75. ncbi request reprint Epidemiology and natural history of NAFLD and NASH
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3289 Woodburn Road, Annadale, VA 22003, USA
    Clin Liver Dis 11:1-16, vii. 2007
    ..NASH-related cirrhosis may have a similar prognosis as cirrhosis from other causes, leading to liver failure or hepatocellular carcinoma...